Annual report
Open the filing on sec.gov
BriaCell Therapeutics Corp. (BCTX)
Nasdaq: BCTX · Pharmaceutical Preparations · West Vancouver, BC · filing with the SEC since 2014
The companyfiscal 2026, as filed
Revenuen/a
Net income-$34.9M-32.7%
Earnings per share$-6.97+88.8%
Operating cash flow-$28.7M-1.7%
Cash$9.9M-6.1%
Debtn/a
Shareholders’ equity$15.6M-10.2%
Shares, diluted5,010,907+1084.3%
Return on equity-224.3%
The recordfrom its filings
Filings in 202622
Newest filingOct 28 · 10-K
Annual reportOct 28, 2026
Quarterly reportJun 9, 2026
Next report due10-Q by Dec 15
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted1
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jul 2026Net income -$34.9MCash from operations -$28.7Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Delisting notice from the exchange
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.